Can-Fite BioPharma Ltd.
CANF · AMEX
Market closed$3.40$0.080000 (+2.41%)After hours $3.24 · -4.71%
Key statistics
Previous close$3.32
Open$3.26
Day high$3.40
Day low$3.22
52-week high$21.00
52-week low$2.56
Market cap1.83M
Volume32.72K
Average volume1.90M
P/E ratio-0.50
Forward P/E—
EPS-6.83
Dividend yield0.00%
Market context
Why it moved
CANF shares edged higher, likely driven by modest technical buying and positive momentum as the stock rebounded from its session low, with no specific company news available to explain the modest uptick amid a broadly volatile market environment.
What is happening
Recent company-specific developments and publisher coverage.
Moomoo · July 2, 2026H.C. Wainwright Maintains Can-Fite BioPharma(CANF.US) With Buy Rating, Raises Target Price to $8Stocktwits · June 26, 2026CANF Stock Pulls Back After Patent-Fueled Surge – Retail Calls It Consolidation Ahead Of Next Leg UpStock Titan · June 17, 2026Can-Fite seeks new drug licenses after $20M in prior dealsStock Titan · April 30, 2026One pancreatic cancer patient stays on Can-Fite drug past 16 monthsStock Titan · March 4, 2026Biotech Can-Fite unlocks $4M to fund drug R&D and clinical trialsStock Titan · March 4, 2026Early trial finds pancreatic cancer drug from Can-Fite is well tolerated Mt Newswire · July 6, 2026Can-Fite BioPharma Completes Enrollment in Phase 3 Study of Potential Plaque Psoriasis Treatment Benzinga · July 6, 2026Can-Fite BioPharma Completes Enrolment Of First 247 Patients In Pivotal Phase 3 Study Evaluating Piclidenoson For Treatment Of Moderate-To-Severe Plaque Psoriasis Benzinga · July 2, 2026HC Wainwright & Co. Reiterates Buy on Can Fite Biopharma, Raises Price Target to $8 Mt Newswire · July 1, 2026Can-Fite Shares Surge After Pancreatic Cancer Study Showed Durable Survival Outcomes Benzinga · July 1, 2026Can-Fite Highlights Survival Outcomes In Pancreatic Cancer Patients Benzinga · June 26, 2026Can-Fite Stock Jumps After Japan Patent Boosts Obesity Drug Case Mt Newswire · June 26, 2026Can-Fite Secures Japanese Patent for Namodenoson's Anti-Obesity Tech; Shares Up Pre-Bell Benzinga · June 26, 2026Can-Fite BioPharma Announces Japan Patent Allowance Covering Namodenoson’s Anti‑Obesity Activity